← All trials
NCT01299922
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2011
- Primary completion
- Mar 1, 2014
- Completion date
- Oct 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Hospital Universitario Fundación AlcorcónLead sponsor
- Hospital San Pedro de AlcantaraCollaborator
- Hospital Universitario Fundación AlcorcónStudy director
- Universidad Complutense de MadridStudy chair
- Hospital General Universitario Gregorio MarañonCollaborator
- Hospital Infanta SofiaCollaborator
- Universidad Complutense de MadridCollaborator
- Universidad de CordobaCollaborator
- Hospital Universitario Infanta LeonorCollaborator
- Hospital Regional Universitario Carlos HayaCollaborator
- Hospital Juan CanalejoCollaborator
- Hospital Universitario de Guadalajara, SpainCollaborator
- University of MalagaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.